OJOG> Vol.2 No.3, September 2012

Unusual primary location of the malignant melanoma, the cervico-vaginal region: 3 cases and literature review

DownloadDownload as PDF (Size:504KB)  HTML    PP. 279-282  

ABSTRACT

Introduction: Malignant melanoma (MM) represents 1% of all cancers and has an incidence of 3% - 7% in the female genital tract, the majority of cases being reported in the vulva. The cervico-vaginal region is an unsual primary location of the malignant mela-noma. Case report: The clinical and morphologic findings of 3 MM patients with cervico-vaginal tumours mimicking cervical polyp in third case. Histologically, the neoplasia was formed by nodules of broad cytoplasmic cells with poorly defined borders with pleomorphic nuclei with prominent nucleolae. Tumor cells were positive for S-100 protein, Melan A, HMB 45 and CD117. The authors discuss three cases of cervico-vaginal melanoma and analyze clinical and prognostic aspects of this disease. Conclusion: Primary MM of the cervix should be considered in the differential diagnosis of cervical malignancies. Early diagnosis is essential in order to warrant a better prognosis, although there are no cases of cure described.

Cite this paper

Hinde, E. , Amal, B. , Hannane, S. , Cherhazade, B. , Abdelaziz, B. , Nawfel, M. and Omar, M. (2012) Unusual primary location of the malignant melanoma, the cervico-vaginal region: 3 cases and literature review. Open Journal of Obstetrics and Gynecology, 2, 279-282. doi: 10.4236/ojog.2012.23058.

References

[1] Seetharamu, N., Ott, P.A. and Pavlick, A.C. (2010) Mucosal melanomas: A case-based review of the literature. The Oncologist, 15, 772-781. doi:10.1634/theoncologist.2010-0067
[2] Irvin Jr., W.P., Bliss, S.A., Rice, L.W., Taylor Jr., P.T. and Andersen, W.A. (1998) Malignant melanoma of the vagina and locoregional control: Radical surgery revisited. Gynecologic Oncology, 71, 476-480. doi:10.1006/gyno.1998.5188
[3] Bonner, J.A., Perez-Tamayo, C., Reid, G.C., Roberts, J.A. and Morley, G.W. (1988) The management of vaginal melanoma. Cancer, 62, 2066-2072. doi:10.1002/1097-0142(19881101)62:9<2066::AID-CNCR2820620933>3.0.CO;2-D
[4] Siozos, C., Bhat, A., Lonsdale, R., Nieto, J.J. and Crocker, S.G. (2005) Malignant melanoma of the uterine cervix. Journal of Obstetrics and Gynaecology, 25, 826-827. doi:10.1080/01443610500338305
[5] Hewitt P. Sequel to a case of recurrent melanosis of both groins and back: The disease reappearing in the brain, heart, pancreas, liver and other organs. Lancet, 1861, 263-264.
[6] Gupta, R., Singh, S. and Mandal, A.K. (2005) Primary malignant melanoma of cervix—A case report. Indian Journal of Cancer, 42, 201-204.
[7] Piura, B. (2008) Management of primary melanoma of the female urogenital tract. The Lancet Oncology, 9, 973-981. doi:10.1016/S1470-2045(08)70254-7
[8] Deshpande, A.H. and Munshi, M.M. (2001) Primary ma- lignant melanoma of the uterine cervix: Report of a case diagnosed by cervical scrape cytology and review of the literature. Diagnostic Cytopathology, 25, 108-111. doi:10.1002/dc.2014
[9] Baruah, J., Roy, K.K., Kumar, S. and Kumar, L. (2009) A rare case of primary malignant melanoma of cervix. Archives of Gynecology and Obstetrics, 280, 453-456. doi:10.1007/s00404-008-0912-0
[10] An, J., Li, B., Wu, L., Lu, H. and Li, N. (2009) Primary malignant amelanotic melanoma of the female genital tract: Report of two cases and review of literature. Melanoma Research, 19, 267-270. doi:10.1097/CMR.0b013e32831993de
[11] Mousavi, A.S., Fakor, F., Nazari, Z., Ghaemmaghami, F., Hashemi, F.A. and Jamali, M. (2006) Primary malignant melanoma of the uterine cervix: Case report and review of the literature. Journal of Lower Genital Tract Disease, 10, 258-263. doi:10.1097/01.lgt.0000229564.11741.4e
[12] Wasef, W.R., Roberts, J.K. and Dixon, G.R. (1999) Primary malignant melanoma of the cervix uteri. Journal of Obstetrics and Gynaecology, 19, 673-674. doi:10.1080/01443619964094
[13] Cantuaria, G., Angioli, R., Nahmias, J., Estape, R. and Penalver, M. (1999) Primarymalignant melanoma of the uterine cervix: Case report and review of the literature. Gynecologic Oncology, 75, 170-174. doi:10.1006/gyno.1999.5491
[14] Miner, T.J., Delgado, R., Zeisler, J., et al. (2004) Primary vaginal melanoma: A critical analysis of therapy. Annals of Surgical Oncology, 11, 34-39. doi:10.1007/BF02524343
[15] Clark, K.C., Butz, W.R. and Hapke, M.R. (1999) Primary malignant melanoma of the uterine cervix: Case report with world literature review. International Journal of Gynecological Pathology 18, 265-273. doi:10.1097/00004347-199907000-00013
[16] Curtin, J.A., Busam, K., Pinkel, D., et al. (2006) Somatic activation of KIT in distinct subtypes of melanoma. Journal of Clinical Oncology, 24, 4340-4346. doi:10.1200/JCO.2006.06.2984
[17] Antonescu, C.R., Busam, K.J., Francone, T.D., et al. (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International Journal of Cancer, 121, 257-264. doi:10.1002/ijc.22681
[18] Torres-Cabala, C.A., Wang, W.L., Trent, J., et al. (2009) Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathology, 22, 1446-1456. doi:10.1038/modpathol.2009.116
[19] Hodi, F.S., Friedlander, P., Corless, C.L., et al. (2008) Major response to imatinib mesylate in KIT-mutated melanoma. Journal of Clinical Oncology, 26, 2046-2051. doi:10.1200/JCO.2007.14.0707
[20] Lutzky, J., Bauer, J. and Bastian, B.C. (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell & Melanoma Research, 21, 492-493. doi:10.1111/j.1755-148X.2008.00475.x
[21] Jiang, X., Zhou, J., Yuen, N.K., et al. (2008) Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clinical Cancer Research, 14, 7726-7732. doi:10.1158/1078-0432.CCR-08-1144

  
comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.